Zusammenfassung
Dieser Beitrag gibt eine Übersicht über den aktuellen Stand der konservativen medikamentösen Therapie der Induratio penis plastica und schließt die orale und intraläsionale Pharmakaapplikation sowie die Iontophorese, die den transdermalen Wirkstofftransport verstärkt, ein. Nach den Kriterien der „evidence-based medicine” sind nur wenige Substanzen geprüft, nur zwei weisen einen Effekt bei oraler und eine bei intraläsionaler Therapie auf. Die Iontophorese wurde nur unter der Verwendung einer Wirkstoffkombination bislang erfolgreich nach harten Kriterien getestet. Weitere prospektive Studien zur Verifizierung erster Erfolge sind unbedingt erforderlich.
Abstract
This paper reviews the current status on conservative therapy of Peyronie's disease including oral and intralesional drug administration, and iontophoresis that enhances the transdermal drug transport. According to the criteria of „evidence-based medicine” only few substances have been proved, only two oral drugs and one for intralesional administration have been demonstrated to be effective. Iontophoresis has been only investigated under the application of a drug combination according to strict criteria. Further prospective studies for verification of first results urgently required.
Schlüsselwörter
Induratio penis plastica - Konservatie Therapie - Iontophorese
Key words
Peyronie's disease - Conservative Therapy - Iontophoresis
Literatur
-
1
Gelbard M K, Dorey F, James K.
The natural history of Peyronie's disease.
J Urol.
1990;
144
1376-1379
-
2
Furlow W L, Swanson H E, Lee R E.
Peyronie's disease: a study of its natural history and treatment with orthovoltage radiotherapy.
J Urol.
1975;
114
69-71
-
3
Poutasse E F.
Peyronie's disease.
J Urol.
1972;
107
419-422
-
4
Hauck E W, Heitz M, Schreiter F, Weidner W.
Induratio penis plastica.
Akt Urol.
1999;
30
386-404
-
5
Zarafonetis C JD.
Antifibrotic therapy with Potaba.
Am J Med Sci.
1964;
248
550-561
-
6
Weidner W, Schroeder-Printzen I, Rudnick J, Krause W, Weiske W H, Drawz B, Rebmann U, Pastermadjeff L, Kallerhoff M, Lenk S, Sperling H, Kliesch S, Schnitker J, Aulitzky W.
Randomized prospective plazebo-controlled therapy of Peyronie's disease (IPP) with Potaba® (Aminobenzoate potassium).
J Urol.
1999;
161 (suppl)
205 abstract 785
-
7
Carson C C.
Potassium para-aminobenzoate for the treatment of Peyronie's disease: is it effective.
Tech Urol.
1997;
3
135-139
-
8
Lemourt Oliva M, Filgueiras López E, Rodríguez Barroso A, González Oramas E, Bornonado R.
Evalución clínica del uso propóleo en la enfermedad de Peyronie.
Arch Esp de Urol.
1998;
51 (suppl 2)
171-176
-
9
Teloken C, Rhoden E L, Meyer Grazziotin T, Da Ros C T, Sogari P R, Vargas Souto C A.
Tamoxifen versus placebo in the treatment of Peyronie's disease.
J Urol.
1999;
162
2003-2005
-
10
Ralph D J, Brooks M D, Bottazo G F, Pryor J P.
The treatment of Peyronie's disease with Tamoxifen.
Br J Urol.
1992;
70
648-651
-
11
Apaydin E, Semerci B, Kefi A, Cikili N, Gürsan A, Mülazimoglu N.
(1998) The use of Tamoxifen in the treatment of Peyronie's disease.
Int J Impotence Res.
1998;
10 (Suppl 3)
S57 abstract 421
-
12
Akkus E, Carrier S, Rehman J, Breza J, Kadioglu A, Lue T F.
Is colchicine effective in Peyronie's disease? A pilot study.
Urology.
1995;
44
291-295
-
13
Pryor J P, Farell C R.
Controlled clinical trial of vitamin E in Peyronie's disease.
Prog Reprod Biol Med.
1983;
9
41-45
-
14
Levine L A, Merrick P F, Lee R C.
Intralesional verapamil injection for the treatment of Peyronie's disease.
J Urol.
1994;
151
1522-1524
-
15
Levine L A.
Treatment of Peyronie's disease with intralesional verapamil injection.
J Urol.
1997;
158
1395-1399
-
16
Levine L A, Goldman K E.
Updated experience with intralesional verapamil injection treatment for Peyronie's disease.
J Urol.
2000;
163 (suppl)
170 abstract 751
-
17
Teloken C, Vaccaro F, Da Ros C, Sogari P, Souto C AV.
Objective evaluation of non-surgical approach for Peyronie's disease.
J Urol.
1996;
155 (suppl)
633A abstract 1290
-
18
Lasser A, Vandenberg T L, Vincent M J, Hellstrom W JG.
Intraplaque verapamil injection for treatment of Peyronie's diseae.
J La State Med Soc.
1998;
150
431-434
-
19
Mirone V, Imbimbo C, Palmieri A, Fusco F.
Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica.
Eur Urol.
1999;
36
327-330
-
20
Rehman J, Benet A, Melman A.
Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study.
Urology.
1998;
51
620-626
-
21
Nicolai M, Cipollone G, Iantorno R, Mastroprimiano A Z, Tenaglia R.
Intralesional verapamil injection versus placebo in Peyronie's disease.
J Urol.
1998;
159 (suppl 5)
117 abstract 450
-
22
Steiger M, Ohlig W, Ludwig G.
Verapamil versus Plazebo als Injektionstherapie der Induratio penis plastica: Langzeitergebnisse einer Doppel-blind-Studie.
Urologe A.
1999;
38 (suppl 1)
S58 abstract V7.6
-
23
Wegner H EH, Andresen R, Knispel H H, Miller K.
Treatment of Peyronie's disease with local interferon-alpha2b.
Eur Urol.
1995;
28
236-240
-
24
Wegner H EH, Andresen R, Knispel H H, Miller K.
Local interferon-alpha2b is not an effective treatment in early-stage Peyronie's disease.
Eur Urol.
1997;
32
190-193
-
25
Judge I S, Wisniewski Z S.
Intralesional interferon in the treatment of Peyronie's disease: a pilot study.
Br J Urol.
1997;
79
40-42
-
26
Ahuja S K, Case J, Vincent M, Sikka S C, Hellstrom W J.
Intralesional injection of alpha interferon 2b in the treatment of Peyronie's disease.
J Urol.
1998;
159 (suppl)
117 abstract 452
-
27
Bryan W W, Novak T E, Vincent M, Sikka S C, Templeton L E, Hellstrom W JG.
Combined theray of interferon alpha 2B (Intron A), and vitamin E in the treatment of Peyronie's disease.
J Urol.
2000;
163 (suppl)
197 abstract 873
-
28
Polat O, Gül O, Özbey I, Özdikici M, Bayraktar Y.
Peyronie's disease: intralesional treatment with interferon-alpha2a and evaluation of the results by magnetic resonance imaging.
Int Urol Nephrol.
1997;
29
465-471
-
29
Duncan M R, Berman B, Nseyo U O.
Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons alpha, beta and gamma.
Scand J Urol Nephrol.
1991;
141
81-94
-
30
Gelbard M K, James K, Riach P, Dorey F.
Collagenase versus placebo in the treatment of Peyronie's disease: a double-blind study.
J Urol.
1993;
149
56-58
-
31
Pastorini S, Marino G, Brigato R, Griffa D, Cocimano V.
La terapia dell'IPP con superossidismutasi per os e iniettiva associata a FIC vasoattiva.
Minerva Urol Nefrol.
1991;
43
75-78
-
32
Primus G.
Orgotein in the treatment of plastic induration of the penis (Peyronie's disease).
Int Urol Nephrol.
1993;
25
169-17
-
33
Rugendorff E W.
Lokalbehandlung der Induratio penis plastica.
Sexualmedizin.
1990;
19
602-608
-
34
Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R.
Betametasone versus placebo nella malattia di la Peyronie.
Arch Ital Urol Androl.
1998;
70
165-168
-
35
Montorsi F, Salonia A, Guazzoni G, Barbieri L, Colombo R, Brausi M, Scattoni V, Rigatti P.
Transdermal electromotive multi-drug administration for Peyronie's disease: preliminary results.
J Androl.
2000;
21
85-90
-
36
Treffiletti S, Annoscia S, Montefiore F, Boccafoschi C.
La iontoforesi nel trattamento conservatio della malattia di La Peyronie: esperienza preliminare.
Arch It Urol.
1997;
LXIX
323-327
-
37
Riedl C R, Plas E, Engelhardt P, Daha K, Pflüger H.
Iontophoresis for treatment of Peyronie's disease.
J Urol.
2000;
163
95-99
Prof. Dr. med W Weidner
Justus-Liebig-Universität Gießen
Urologische Klinik und Poliklinik
Klinikstraße 29
35385 Gießen
Telefon: Tel.: 0641-9944501
Fax: Fax: 0641-9944509
eMail: E-mail: wolfgang.weidner@chiru.med.uni-gießen.de
